Use of Sedatives and Neuromuscular-Blocking Agents in Mechanically Ventilated Patients with COVID-19 ARDS.

COVID-19 acute respiratory distress syndrome neuromuscular-blocking agents sedation

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
20 Nov 2021
Historique:
received: 30 09 2021
revised: 12 11 2021
accepted: 18 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

To assess differences in the use of analgesics, sedatives and neuromuscular-blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 or other conditions. Retrospective observational cohort study, single-center tertiary Intensive Care Unit. COVID-19 patients with ARDS (March-May 2020) and non-COVID ARDS patients (2017-2020) on mechanical ventilation and receiving sedation for at least 48 h. A total of 39 patients met the inclusion criteria in each group, with similar demographics at baseline. COVID-19 patients had a longer duration of MV (median 22 (IQRs 16-29) vs. 9 (6-18) days; The duration and consumption of sedatives and NMBA was significantly increased in patients with COVID-19 related ARDS than in non-COVID ARDS. Different sedation strategies and protocols might be needed in COVID-19 patients with ARDS, with potential implications on long-term complications and drugs availability.

Identifiants

pubmed: 34835518
pii: microorganisms9112393
doi: 10.3390/microorganisms9112393
pmc: PMC8624865
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Anesth Analg. 2020 Oct;131(4):e198-e200
pubmed: 32675640
Lancet Respir Med. 2021 Mar;9(3):218-219
pubmed: 33428873
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1079-1080
pubmed: 32881583
J Pharm Pract. 2021 Jul 19;:8971900211033138
pubmed: 34281428
PLoS One. 2021 Jul 27;16(7):e0253778
pubmed: 34314422
J Pain Symptom Manage. 2001 Aug;22(2):672-87
pubmed: 11495714
Lancet Respir Med. 2021 Mar;9(3):239-250
pubmed: 33428871
Intensive Care Med. 2020 Dec;46(12):2342-2356
pubmed: 33170331
Nutr Metab Cardiovasc Dis. 2020 Oct 30;30(11):1899-1913
pubmed: 32912793
Am J Health Syst Pharm. 2021 Oct 25;78(21):1952-1961
pubmed: 33993212
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
Ann Pharmacother. 2021 Jun 2;:10600280211021925
pubmed: 34075807
Clin Neurophysiol. 2021 Jul;132(7):1733-1740
pubmed: 33875374
Crit Care Med. 2010 Aug;38(8):1674-84
pubmed: 20581667
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452

Auteurs

Amédée Ego (A)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Lorenzo Peluso (L)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Julie Gorham (J)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Alberto Diosdado (A)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Giovanni Restuccia (G)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Jacques Creteur (J)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Fabio Silvio Taccone (FS)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Classifications MeSH